Get the Stockscreener App
118.51
1.17%
1.37
Axsome Therapeutics Inc stock is traded at $118.51, with a volume of 727.98K.
It is up +1.17% in the last 24 hours and up +15.56% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$117.14
Open:
$118.43
24h Volume:
727.98K
Relative Volume:
1.19
Market Cap:
$5.91B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-18.15
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
+8.51%
1M Performance:
+15.56%
6M Performance:
-13.97%
1Y Performance:
+36.05%
1-Day Range:
$117.58
$120.50
1-Week Range:
$109.40
$120.50
52-Week Range:
$75.56
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
118.51 | 5.55B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Initiated | Oppenheimer | Outperform |
| Apr-07-25 | Initiated | Jefferies | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Axsome stock rating reiterated at Outperform by RBC, citing FDA flexibility - Investing.com
Vanguard Group Inc. Sells 25,537 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Wyckoff Accumulation Phase Possible in Axsome Therapeutics Inc.2025 Big Picture & Growth Focused Investment Plans - classian.co.kr
Fox Run Management L.L.C. Acquires 7,465 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Purchased by Invesco Ltd. - MarketBeat
Deutsche Bank AG Cuts Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Nuveen LLC Invests $48.19 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Quant Tools Rank Axsome Therapeutics Inc. as High Risk High RewardJuly 2025 Technicals & Weekly High Conviction Trade Ideas - thegnnews.com
Versor Investments LP Acquires Shares of 19,615 Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Axsome Therapeutics Inc. Approaches Support With Recovery in SightJuly 2025 Sector Moves & Stock Market Timing Techniques - sundaytimes.kr
What's Going On With Tonix Pharma Stock Monday?Tonix Pharmaceuticals (NASDAQ:TNXP) - Benzinga
Virtu Financial LLC Takes $931,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Informed Momentum Co LLC Purchases Shares of 42,222 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Can Axsome Therapeutics Inc. continue delivering strong returnsWeekly Profit Analysis & Fast Exit Strategy with Risk Control - thegnnews.com
Connor Clark & Lunn Investment Management Ltd. Has $20.52 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
XTX Topco Ltd Sells 9,794 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Cantor Fitzgerald Has Positive View of AXSM FY2026 Earnings - MarketBeat
Equities Analysts Set Expectations for AXSM Q3 Earnings - MarketBeat
HC Wainwright Issues Negative Estimate for AXSM Earnings - MarketBeat
Cantor Fitzgerald Issues Negative Forecast for AXSM Earnings - MarketBeat
Leerink Partnrs Issues Positive Forecast for AXSM Earnings - MarketBeat
Equities Analysts Issue Forecasts for AXSM Q3 Earnings - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2025 Earnings Call Transcript - MSN
Royal Bank Of Canada Raises Axsome Therapeutics (NASDAQ:AXSM) Price Target to $189.00 - MarketBeat
TD Asset Management Inc Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics' (AXSM) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Axsome outlines late-stage pipeline advancements and targets cash flow positivity amid 72% revenue growth - MSN
Axsome Therapeutics (NASDAQ:AXSM) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Federated Hermes Inc. Acquires Shares of 25,990 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics Jumps 5% as Q2 Revenue Surpasses Projections - MSN
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Axsome Therapeutics Inc Stock (AXSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Murdock Hunter R. | General Counsel |
Jun 20 '25 |
Option Exercise |
29.91 |
7,500 |
224,325 |
7,500 |
| Murdock Hunter R. | General Counsel |
Jun 23 '25 |
Option Exercise |
29.91 |
6,014 |
179,879 |
6,014 |
| Murdock Hunter R. | General Counsel |
Jun 20 '25 |
Sale |
102.47 |
7,500 |
768,525 |
0 |
| Murdock Hunter R. | General Counsel |
Jun 23 '25 |
Sale |
100.12 |
6,014 |
602,122 |
0 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):